Empagliflozin/linagliptin/metformin

Empagliflozin/linagliptin/metformin is a combination drug used in the treatment of type 2 diabetes. It is a combination of three active ingredients: empagliflozin, linagliptin, and metformin.

Composition[edit | edit source]

The drug is composed of three active ingredients:

Empagliflozin is a SGLT2 inhibitor that works by preventing the kidneys from reabsorbing glucose back into the blood, thereby promoting the excretion of glucose in the urine.

Linagliptin is a DPP-4 inhibitor that works by increasing the levels of incretin hormones in the body, which in turn increases insulin production in response to meals and decreases the amount of glucose produced by the liver.

Metformin is a biguanide that works by decreasing glucose production in the liver and increasing the sensitivity of muscle cells to insulin, which helps them to remove glucose from the blood.

Indications[edit | edit source]

Empagliflozin/linagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.

Side Effects[edit | edit source]

Common side effects of empagliflozin/linagliptin/metformin include urinary tract infection, hypoglycemia, and upper respiratory tract infection. Serious side effects may include lactic acidosis, pancreatitis, and hypotension.

Contraindications[edit | edit source]

Empagliflozin/linagliptin/metformin is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis. It is also contraindicated in patients with a history of serious hypersensitivity reaction to empagliflozin, linagliptin, or metformin.